Oceanía · Actualidad · The Mercury

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Publicado por The Mercury · Australia hace 12 h

Alterity Therapeutics has presented additional analyses of its Phase 2 trial showing the 50mg twice-daily dose of its lead drug candidate ATH434 slowed functional ...

Leer el artículo completo en The Mercury Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.themercury.com.au)

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

También te puede interesar

Major parties all flag big cuts to immigration numbers

Behind the scenes at Perth’s most controversial expo

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

A family's heartbreak after watching a loved one die from Australia's no.1 killer

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Compartir

También te puede interesar

Major parties all flag big cuts to immigration numbers

Behind the scenes at Perth’s most controversial expo

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

A family's heartbreak after watching a loved one die from Australia's no.1 killer

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’